Beta-cell hypersecretion and not reduced hepatic insulin extraction is the main cause of hyperinsulinemia in obese nondiabetic subjects.
Obesity is characterized by peripheral hyperinsulinemia, for which either beta-cell hypersecretion, diminished hepatic insulin extraction, or both may be responsible. To clarify this issue, we investigated insulin secretion and hormone hepatic extraction in 18 nondiabetic obese patients (body mass index [BMI], 39 +/- 1.3 kg/m2) and 18 healthy, lean control subjects (BMI, 21.3 +/- 0.7 kg/m2). Body fat distribution was calculated by measuring the waist to hip ratio (WHR). A highly reduced tissue insulin sensitivity (2.4 +/- 0.5 v 9.5 +/- 1.5 10(4).min-1/[microU/mL], P > .0005) and glucose effectiveness, ie, glucose's ability to stimulate its own disappearance at basal insulin (16 +/- 2 v 30 +/- 3 10(3).min-1, P > .005), were found in the overweight subjects compared with the controls. The basal (76 +/- 14 v 37 +/- 4 pmol/L/min) and total (377,848 +/- 5,562 v 16,864 +/- 1,850 pmol/L) prehepatic insulin secretion and the basal (15 +/- 2 v 7 +/- 0.7 pmol/L/min) and total (8,286 +/- 2,009 v 2,840 +/- 210 pmol/L) posthepatic insulin delivery were significantly higher in the overweight subjects compared with the controls (P < .005), whereas the mean hepatic insulin extraction did not differ (77.8% +/- 2.6% v 79.5% +/- 2.6%). A significant inverse correlation was found between the hepatic insulin extraction and the WHR (r = .5, P > .04), signifying the importance of fat distribution in insulin metabolism. The obese patients were subdivided into two subgroups according to their glucose tolerance; eight patients exhibited a normal tolerance and the remaining 10 were intolerant.(ABSTRACT TRUNCATED AT 250 WORDS)
Kautzky-Willer
A
A
Second Medical Department, University of Vienna, Austria.
Pacini
G
G
Ludvik
B
B
Schernthaner
G
G
Prager
R
R
D000005:Abdomen / Q000033:anatomy & histology; D000328:Adult; D001794:Blood Pressure / Q000502:physiology; D002096:C-Peptide / Q000097:blood / Q000493:pharmacokinetics; D002784:Cholesterol / Q000097:blood; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000097:blood; D005260:Female; D005951:Glucose Tolerance Test; D006615:Hip / Q000033:anatomy & histology; D006801:Humans; D006946:Hyperinsulinism / Q000097:blood / Q000209:etiology*; D007328:Insulin / Q000032:analysis / Q000097:blood* / Q000493:pharmacokinetics; D007515:Islets of Langerhans / Q000166:cytology* / Q000378:metabolism* / Q000502:physiology; D008099:Liver / Q000737:chemistry / Q000378:metabolism*; D008297:Male; D008954:Models, Biological; D009765:Obesity / Q000097:blood / Q000150:complications*; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
D002096:C-Peptide; D007328:Insulin; D014280:Triglycerides; D002784:Cholesterol